Wedbush has begun its coverage on Jade Biosciences (JBIO, Financial), assigning the company an Outperform rating and a price target of $17. The firm's analysis highlights Jade Biosciences' strategic focus on its autoimmune pipeline, notably featuring JADE-001. This monoclonal antibody is designed to target the APRIL pathway specifically in treating IgA nephropathy.
The research underscores the potential of JADE-001 to stand out among other anti-APRIL treatments. Wedbush suggests that with previous developments in the field providing validation of the target, Jade Biosciences is pursuing a relatively lower-risk strategy. The firm believes that these factors position Jade Biosciences favorably in advancing its pipeline.
